The biggest stories of the day delivered to your inbox.

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...

Using no code AI platforms can speed up development and reduce costs. Many platforms offer features for automation, data ...